SEC Form 4 · accession 0001209191-19-003174
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth A. Barrett
Officer — Chief Executive Officer
Period of report
Jan 3, 2019
Accepted (ET)
Jan 9, 2019 · 8:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001668243
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $47.57 | Jan 3, 2018 | A | 277,432 | A | — | Jan 3, 2029 | Ordinary Shares | 277,432 | 277,432 | D |
| Restricted Stock UnitF2,F3 | — | Jan 3, 2018 | A | 317,065 | A | — | — | Ordinary Shares | 317,065 | 317,065 | D |
Explanation of responses
- F133% of the shares underlying the stock option will vest on January 3, 2020 and 2.778% of the remaining shares will vest in equal monthly installments thereafter.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F333% of the RSUs will vest on January 3, 2020 and the remaining RSUs will vest 2.778% in equal monthly installments thereafter.